SCHEMBL6714514

SCHEMBL6714514

c1ccc(CNNc2ccccn2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
CHRM2 P08172 1/20 0.49
CXCR4 P61073 1/20 0.48
FABP1 P07148 1/20 0.47
FABP6 P51161 1/20 0.47
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK10 P53779 1/20 0.44
GFER P55789 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL229311 0.80 CXCR4 (0.68) CYP1A2MAOAMAOBSMN1; SMN2CHRM2
SCHEMBL30487250 0.80 CXCR4 (0.68) CYP1A2MAOAMAOBSMN1; SMN2CHRM2
SCHEMBL20859514 0.79 KDM4E (0.73) MAOAMAOBSMN1; SMN2CHRM2KDM4E
SCHEMBL10405315 0.76 MEN1 (0.61) CYP1A2SMN1; SMN2CXCR4FABP1FABP6
SCHEMBL2775016 0.76 CXCR4 (0.47) CYP1A2SMN1; SMN2CXCR4FABP1FABP6
SCHEMBL18747185 0.76 MAOA (0.55) CYP1A2MAOAMAOBSMN1; SMN2CHRM2
SCHEMBL14824934 0.75
SCHEMBL230222 0.74 CHRM2 (0.70) MAOAMAOBSMN1; SMN2CHRM2KDM4E
SCHEMBL29438821 0.74 CHRM2 (0.70) MAOAMAOBSMN1; SMN2CHRM2KDM4E
SCHEMBL18411909 0.74 MAOA (0.53) MAOAMAOBSMN1; SMN2CHRM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK CYP1A2 838/4885MAOA 1156/4885MAOB 981/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A CYP1A2 447/4885MAOA 706/4885MAOB 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.